Nuvation Bio Inc (NUVB)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Nuvation Bio Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 6.30 $ — 56% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Analysts & Price Target
The price target sits 102.9% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 7
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.28 | -0.28 – -0.28 | 203 | 43.3% | 1 |
| 12/31/2027 | -0.06 | -0.06 – -0.06 | 290 | 78.6% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.14 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.15 | – | 6 | 2,063.30 | -865.80 | -46 | -46 |
| 2025: Q1 | -0.16 | – | 3 | 1,068.20 | -1,726.20 | -43 | -43 |
| 2025: Q2 | -0.17 | – | 5 | 236.80 | -1,220.90 | -48 | -48 |
| 2025: Q3 | -0.16 | – | 13 | 1,704.70 | -425.20 | -53 | -53 |
| 2025: Q4 | -0.11 | – | 42 | 633.10 | -87.40 | -30 | -30 |
| 2026: Q1 | 0.01 | – | 83 | 2,598.70 | 6.50 | 5 | 5 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | – | -1 | -1 | -0.01 | -1 | -1 | 0 |
| 2019 | – | -32 | -34 | -0.16 | -24 | 118 | 121 |
| 2020 | 0 | -44 | -42 | -0.19 | -37 | 215 | 222 |
| 2021 | 0 | -93 | -87 | -0.44 | -68 | 746 | 776 |
| 2022 | 0 | -120 | -104 | -0.48 | -96 | 655 | 672 |
| 2023 | 0 | -100 | -76 | -0.35 | -68 | 605 | 621 |
| 2024 | 8 | -593 | -568 | -2.11 | -130 | 464 | 541 |
| 2025 | 63 | -213 | -205 | -0.60 | -173 | 306 | 595 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Nuvation Bio Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, konzentriert sich auf die Entwicklung von Produktkandidaten zur Krebsbehandlung.
| Employees | 307 |
|---|---|
| Headquarters | New York, NY |
| Address | 1500 Broadway, 10036 New York, United States |
| Phone | 332 208 6102 |
| Website | nuvationbio.com |
| IPO Date | 24. Aug 2020 |
| ISIN | US67080N1019 |
Management
| Name | Title | Birth Year |
|---|---|---|
| David T. Hung M.D. | Founder, President, CEO & Chairman | 1958 |
| Philippe Pierre Sauvage | CFO & Principal Financial Officer | 1978 |
| Gary Hattersley Ph.D. | Chief Scientific Officer | 1967 |
| Moses Makunje CPA | VP of Finance and Principal Accounting & Financial Officer | 1979 |
| David C. Hanley Ph.D. | Chief Technical Operations Officer | 1970 |
| Robert DeVita | Vice President of Corporate Development & Investor Relations | – |
| Stephen Dang Ph.D. | Chief Legal Officer & Corporate Secretary | – |
| Stacy Markel | Chief People Officer | 1965 |
| Kerry A. Wentworth | Chief Regulatory Officer | 1973 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Sauvage Philippe | Chief Financial Officer | Other | 1 | 1.97 | 2 |
| 15. Jul 2026 | Sauvage Philippe | Chief Financial Officer | Other | 39,999 | 2.17 | 86,798 |
| 17. Apr 2026 | Dongfang Liu | Insider | Sell | 50,000 | 5.02 | 251,000 |
| 17. Apr 2026 | Kerry Wentworth | Insider | Sell | 36,750 | 5.01 | 184,118 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.